Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share ...

Under the proposed deal, CD&R would acquire a 50% controlling interest in Opella, while Sanofi would retain a substantial stake, positioning itself as a key player in the company’s future ...

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially. The French pharma group confirmed ...

The key reason I highlight is the ongoing process of spinning off its consumer healthcare unit, which is called Opella. So, on the Q4 earnings call, Francois Roger, Sanofi's CFO, made the ...

Sanofi is now in exclusive talks with private equity company Clayton Dubilier & Rice over the sale of a controlling stake in its consumer health business Opella, as the French government seeks to ...

Banks including Goldman Sachs Group Inc. and Citigroup Inc. have wrapped up a €7.45 billion ($8.1 billion) sale of leveraged loans and high-yield bonds to finance Clayton Dubilier & Rice’s purchase of ...

With high regard for China's vast market potential and dynamic innovation ecosystem, Opella, Sanofi's consumer healthcare ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

In October 2023, Sanofi announced that it intends to separate the Consumer HealthCare unit through the creation of a publicly listed entity headquartered in Paris to be called Opella. Sanofi has ...

Sanofi plans share buybacks, signals more deals post Opella sale Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with ...

The debt package for the unit, which is called Opella, was one of the most hotly anticipated financing deals to come to market this year in Europe and the US. It included €5.2 billion-equivalent ...